SCF LEAD RANKING REPORT
PROJECT AMMONEX-HE
Ethnobioprospecting Lead Prioritization for Hepatic Encephalopathy Ammonia Modulation
Document Code: SCF-AMMONEX-HE-LR-0001
Development Stage: Discovery → Hit-to-Lead Selection
Target Indication: Hepatic Encephalopathy (HE)
Primary Clinical Objective:
Reduce systemic ammonia burden by targeting the Gut–Liver–Brain Axis while improving hepatic metabolic resilience and minimizing neurotoxicity.
I. SCF PATHOGENESIS TARGET MAP
Primary Fault Nodes
Rank | Fault Node | Therapeutic Priority |
1 | Gut ammonia production | Critical |
2 | Urea cycle insufficiency | Critical |
3 | Gut barrier dysfunction | High |
4 | Neuroinflammation | High |
5 | Astrocyte glutamine accumulation | High |
6 | Oxidative stress | Moderate |
7 | Dysbiosis | Moderate |
SCF Pathogenesis alignment performed according to SCF Fault Architecture methodology.
II. LEAD RANKING CRITERIA
SCF Five Principles
Principle | Weight |
Targeted Drug Action | 25% |
Pharmacokinetic Optimization | 20% |
Metabolic Efficiency | 20% |
Resistance Prevention | 15% |
Safety Profile | 20% |
Derived from SCF Synergistic Compatibility Principles.
III. LEAD CANDIDATE SHORTLIST
TIER 1 — PRIMARY DEVELOPMENT CANDIDATES
Candidate 1
Phyllanthus niruri
SCF Role
Primary Hepatic Ammonia Regulator
Mechanistic Rationale
Mechanism | Relevance |
Hepatoprotection | High |
Oxidative stress reduction | High |
Nitrogen metabolism support | Moderate |
Anti-inflammatory | High |
Gut-liver support | High |
Development Advantages
- Extensive human exposure history
- Well-characterized phytochemistry
- Favorable safety profile
- Suitable for semi-synthetic optimization
Preliminary SCF Scores
Metric | Score |
TSSM | 8.7 |
HSV-F² | 8.5 |
SV-EQ | 8.8 |
MGIS | 8.4 |
SPCI | 8.9 |
Composite Score
89/100
Candidate 2
Genipa americana
Amazonian Hepatoprotective Lead
Database designation:
Hepatoprotective iridoid source.
Mechanistic Rationale
Mechanism | Relevance |
Hepatocyte protection | High |
Redox regulation | High |
Metabolic stabilization | High |
Anti-inflammatory | Moderate |
Advantages
- Novel development space
- Strong ethnomedical alignment
- Lower competitive saturation
Composite Score
87/100
Candidate 3
Ganoderma spp.
Database designation:
Immunomodulatory triterpene and β-glucan source.
Mechanistic Rationale
Mechanism | Relevance |
Gut barrier support | High |
Immune modulation | High |
Hepatic support | Moderate |
Safety harmonization | Very High |
Composite Score
85/100
TIER 2 — AMMONIA PRODUCTION MODULATORS
Candidate 4
Terminalia chebula
SCF Role
Gut Ammonia Suppression Candidate
Potential Actions
- Polyphenol-mediated microbial regulation
- Urease modulation hypothesis
- Barrier stabilization
Composite Score
83/100
Candidate 5
Cichorium intybus
SCF Role
Prebiotic Nitrogen-Axis Modulator
Mechanistic Advantages
- Inulin source
- Microbiome remodeling
- Gut-liver signaling support
Composite Score
82/100
TIER 3 — NEUROPROTECTIVE SUPPORT LEADS
Candidate 6
Curcuma longa
SCF Role
Neuroinflammatory Signal Suppressor
Advantages
- NF-κB pathway modulation
- Astrocyte protection
- Oxidative stress reduction
Composite Score
81/100
Candidate 7
Silybum marianum
SCF Role
Safety Harmonizer
Advantages
- Extensive hepatic clinical history
- Strong translational feasibility
- CMC-friendly development
Composite Score
80/100
IV. DEVELOPMENT CANDIDATE NOMINATION
Lead Candidate Selection
AMX-101
Working API Name: PHYLAMMIDE™
Source
Phyllanthus niruri
Proposed SCF Classification
SCF-HM-01
(Hepatic Metabolic Ammonia Modulator)
Discovery Justification
Highest overall balance of:
- Hepatic protection
- Metabolic stabilization
- Safety
- Development feasibility
- Regulatory tractability
V. FIRST SCF FIBONACCI STACK PROTOTYPE
Fibonacci Role | Candidate |
Target Modulator (1) | Phyllanthus niruri |
Safety Harmonizer (1) | Silybum marianum |
Metabolic Stabilizer (2) | Genipa americana |
Metabolic Stabilizer (2) | Ganoderma spp. |
Absorption Enhancer (3) | Phospholipid carrier |
Absorption Enhancer (3) | Inulin matrix |
Absorption Enhancer (3) | Medium-chain lipid carrier |
Supportive Agent (5) | Curcuma longa |
Supportive Agent (5) | Terminalia chebula |
Supportive Agent (5) | Antioxidant flavonoid fraction |
Supportive Agent (5) | β-glucan fraction |
Supportive Agent (5) | Mucosal support fraction |
Workflow architecture follows SCF Ethnobioprospecting + Synergistic API Design methodology.
VI. RECOMMENDED NEXT STAGE
Trigger:
API DISCOVERY
This will generate:
- Full SCF API Discovery Profile
- Novel API scaffold hypothesis
- Molecular target mapping
- MoA and MeA characterization
- Pharmacokinetic engineering strategy
- SCF synergy scorecard
- IND-oriented preclinical development blueprint
MASTER REGISTRY INDEX
SCF-AMMONEX-HE-LR-0001 — Lead Ranking Report
SCF-AMMONEX-HE-API-0002 — Candidate API Development Program
SCF-AMMONEX-HE-SEF-0003 — Synergy Evaluation Framework
SCF-AMMONEX-HE-PRECL-0004 — Preclinical Translation Package
SCF-AMMONEX-HE-IND-0005 — IND Readiness Architecture